Literature DB >> 14985264

Characteristics of T-cell receptor repertoire and myelin-reactive T cells reconstituted from autologous haematopoietic stem-cell grafts in multiple sclerosis.

Wei Sun1, Uday Popat, George Hutton, Ying C Q Zang, Robert Krance, George Carrum, Geoffrey A Land, Helen Heslop, Malcolm Brenner, Jingwu Z Zhang.   

Abstract

Multiple sclerosis is thought to involve aberrant immune responses to myelin autoantigens. Haematopoietic stem-cell transplantation (HSCT) is in clinical trials for progressive multiple sclerosis based on the rationale that it destroys aberrant immune system, while recapitulation of lymphocyte ontogeny might alter the immune system and slow down disease progression. This study was undertaken to analyse characteristics of the T-cell receptor (TCR) repertoire, serum cytokine profile and the T-cell responses to myelin basic protein (MBP) in the reconstituted immune system in progressive multiple sclerosis. The study revealed that, following autologous HSCT, the T-cell immunity recovered in two distinctive phases. The first phase was characterized by limited T-cell immunity as a result of selective expansion of pre-existing T cells commonly expressing the TCR beta chain variable region (TCR BV) 20 and increased serum cytokine production during the first several months. The second phase of T-cell reconstitution coincided with increased thymic T-cell output 9-12 months after HSCT. T cells reconstituted from stem-cell grafts had the distinctive properties of comprehensive T-cell immunity and a broad TCR repertoire. T cells recognizing MBP were initially depleted by immunoablation and rapidly expanded from the reconstituted T-cell repertoire in 12 months. The reconstituted MBP-reactive T cells exhibited a broader epitope recognition repertoire while maintaining the same skewed reactivity pattern compared with that seen at baseline. The findings have important implications in the understanding of the role of HSCT as a potential treatment for multiple sclerosis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14985264     DOI: 10.1093/brain/awh117

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  27 in total

Review 1.  Evaluation of TCR repertoire diversity in patients after hematopoietic stem cell transplantation.

Authors:  Yangqiu Li; Ling Xu
Journal:  Stem Cell Investig       Date:  2015-09-28

Review 2.  Immune mechanisms underlying the beneficial effects of autologous hematopoietic stem cell transplantation in multiple sclerosis.

Authors:  David Gosselin; Serge Rivest
Journal:  Neurotherapeutics       Date:  2011-10       Impact factor: 7.620

Review 3.  Five Questions Answered: A Review of Autologous Hematopoietic Stem Cell Transplantation for the Treatment of Multiple Sclerosis.

Authors:  Harold L Atkins; Mark S Freedman
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

4.  Autologous hematopoietic SCT normalizes miR-16, -155 and -142-3p expression in multiple sclerosis patients.

Authors:  L C M Arruda; J C C Lorenzi; A P A Sousa; D L Zanette; P V B Palma; R A Panepucci; D S Brum; A A Barreira; D T Covas; B P Simões; W A Silva; M C Oliveira; K C R Malmegrim
Journal:  Bone Marrow Transplant       Date:  2014-12-08       Impact factor: 5.483

5.  Characterization of the inflammatory cells in ascending thoracic aortic aneurysms in patients with Marfan syndrome, familial thoracic aortic aneurysms, and sporadic aneurysms.

Authors:  Rumin He; Dong-Chuan Guo; Wei Sun; Christina L Papke; Senthil Duraisamy; Anthony L Estrera; Hazim J Safi; Chul Ahn; L Maximilian Buja; Frank C Arnett; Jingwu Zhang; Yong-Jian Geng; Dianna M Milewicz
Journal:  J Thorac Cardiovasc Surg       Date:  2008-06-12       Impact factor: 5.209

6.  The development of hematopoietic and mesenchymal stem cell transplantation as an effective treatment for multiple sclerosis.

Authors:  Jameson P Holloman; Calvin C Ho; Arushi Hukki; Jennifer L Huntley; G Ian Gallicano
Journal:  Am J Stem Cells       Date:  2013-06-30

Review 7.  Autologous bone marrow transplantation for the treatment of multiple sclerosis.

Authors:  Marta Radaelli; Arianna Merlini; Raffaella Greco; Francesca Sangalli; Giancarlo Comi; Fabio Ciceri; Gianvito Martino
Journal:  Curr Neurol Neurosci Rep       Date:  2014-09       Impact factor: 5.081

Review 8.  Immune reconstitution therapy (IRT) in multiple sclerosis: the rationale.

Authors:  Dimitrios Karussis; Panayiota Petrou
Journal:  Immunol Res       Date:  2018-12       Impact factor: 2.829

9.  Autologous hematopoietic stem cell transplantation as a treatment option for aggressive multiple sclerosis.

Authors:  Nikolai Pfender; Riccardo Saccardi; Roland Martin
Journal:  Curr Treat Options Neurol       Date:  2013-06       Impact factor: 3.598

Review 10.  Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis.

Authors:  Paolo A Muraro; Roland Martin; Giovanni Luigi Mancardi; Richard Nicholas; Maria Pia Sormani; Riccardo Saccardi
Journal:  Nat Rev Neurol       Date:  2017-06-16       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.